Otsuka (OTCMKTS:OTSKY) Shares Gap Down - Time to Sell?

Key Points

• Otsuka shares gapped down premarket from $35.06 to $33.68 and were last trading at $33.68, down about 1.8% on very light volume (454 shares).
• Analyst coverage is mixed with a consensus rating of "Hold" (1 Buy, 2 Hold, 1 Sell); notable moves include Morgan Stanley upgrading to Overweight while Goldman Sachs cut from Strong-Buy to Strong-Sell.
• Key fundamentals: market cap ~$36.36B, PE ~14.7, very low debt-to-equity (~0.05), and the stock sits just above its 50-day ($33.38) and well above its 200-day ($29.93) moving averages.

Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY - Get Free Report)'s stock price gapped down prior to trading on Friday . The stock had previously closed at $35.06, but opened at $33.68. Otsuka shares last traded at $33.68, with a volume of 454 shares trading hands.

Wall Street Analyst Weigh In

OTSKY has been the subject of several analyst reports. Zacks Research upgraded Otsuka from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 31st. Morgan Stanley upgraded Otsuka to an "overweight" rating in a report on Friday, January 23rd. The Goldman Sachs Group cut Otsuka from a "strong-buy" rating to a "strong sell" rating in a report on Friday, February 27th. Finally, UBS Group upgraded Otsuka to a "hold" rating in a report on Tuesday, January 27th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold".

Otsuka Trading Down 1.8%

The firm has a market capitalization of $36.36 billion and a PE ratio of 14.72. The company has a current ratio of 2.17, a quick ratio of 1.67 and a debt-to-equity ratio of 0.05. The business has a fifty day moving average price of $33.38 and a two-hundred day moving average price of $29.93.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm's core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.